Cancer Options Blog

This blog is a way of sharing, supporting and educating anyone dealing with a cancer-related illness about the options and treatments they have at their disposal.

You're browsing: Home » Blog » Cancer Options, News » Blog article: Newest isotope used in brachytherapy for prostate cancer

FOR IMMEDIATE RELEASE: July 20, 2007

Scientific abstracts on the newest isotope used in brachytherapy for prostate cancer–IsoRay Medical’s Proxcelan™ with Cesium-131–presented at the American Association of Physicists in Medicine (AAPM) annual conference, July 22-26

RICHLAND, Washington - Noted medical researchers from around the country will gather at the 26th annual American Association of Physicists in Medicine (AAPM) conference in Minneapolis, MN, July 22-26, to present results of their studies focusing on Proxcelan™ with Cesium-131. The abstracts illustrate the radiobiological characteristics and related dosimetric outcomes in treatment planning using Proxcelan™ with Cesium-131– the newest isotope used in brachytherapy for the treatment of prostate cancer and the first breakthrough in more than 20 years.

(Proxcelan™ with Cesium-131 will be spotlighted in booth #138 at AAPM).

These studies will add to the growing body of scientific research building for Proxcelan™ with Cesium-131, a proprietary product of IsoRay Medical™ - a wholly owned subsidiary of a public company, IsoRay, Inc. (“IsoRay”) (AMEX Symbol: ISR), based in Richland, WA.

“Innovations are important to the future of medical care, and I believe that Proxcelan with Cesium-131 represents one of the biggest advancements to come along in many years for prostate brachytherapy,” said Bradley R. Prestidge, MD, President/CEO/Medical Director of the Texas Cancer Clinic in San Antonio, Texas.

A multi-institutional trial, with Dr. Prestidge as principal investigator, concluded earlier this year that low dose (LDR) brachytherapy treatment using Cesium-131 for prostate cancer “…has come into widespread use; and the clinical results of this trial are mature enough to be of immediate, important, practical use to practitioners.”

“Several of the papers being presented at AAPM confirm earlier results regarding Cesium-131’s excellent dosimetric properties and applicability for prostate cancer,” said IsoRay Medical Director Steven Kurtzman, MD, Director of Brachytherapy for Western Radiation Oncology in San Mateo, California.

The four abstracts presented on Proxcelan™ with Cesium-131 during the course of the five-day conference include:

“Cesium-131 Prostate Brachytherapy and Treatment Plan Parameters”
Authors: Sutlief, S. & Wallner, K

“Dosimetric Comparison of Cesium-131 and Palladium-103 for Permanent Prostate Brachytherapy”
Author: Musmacher, J.

“Determination of TG-43 Parameters for Cs-131 Model CS-1R2 Seed Using Radiochromic EBT Film Dosimetry”
Author: Chiu-Tsau, S.

“Dosimetric Characterization of Model CS-1 Cesium-131 Source by Thermoluminescence Dosimetry in Liquid Water”
Author: Tailor, R. & Ibbott, G.

Share This Post - instructions included

PLEASE post a comment below